Is Liceko® more effective than Nix® / Lyclear® against head lice?

ISRCTN ISRCTN45553737
DOI https://doi.org/10.1186/ISRCTN45553737
Secondary identifying numbers CTPN01
Submission date
19/04/2011
Registration date
24/05/2011
Last edited
06/09/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Ian F Burgess
Scientific

Medical Entomology Centre
Insect Research & Development Limited
6 Quy Court
Colliers Lane
Stow-cum-Quy
Cambridge
CB25 9AU
United Kingdom

Phone +44 (0)122 381 0070
Email ian@insectresearch.com

Study information

Study designSingle-centre randomised two-arm comparative study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomised, controlled, assessor-blind, clinical trial to compare Liceko® with Nix® / Lyclear® 1% permethrin creme rinse in the treatment of head lice.
Study objectivesTo confirm that Liceko® is effective to kill head lice and their eggs using two applications in comparison with two applications of Nix® / Lyclear®, and to identify any significant difference in performance (superiority) of one product over the other in the eradication of head lice.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedHead louse infestation
InterventionGroup A Liceko®: The product will be applied directly to dry hair. Sufficient product will be applied to saturate the hair and scalp. The product will be left in place for 20 minutes before being shampooed and rinsed off with water.

Group B Nix® / Lyclear® : The product will be applied to washed and towel dried hair. Sufficient product will be applied to saturate the hair and scalp. The product will be left in place for 10 minutes before being rinsed off with water.

For both treatments the product will be reapplied at Day 7.
Intervention typeOther
Primary outcome measureCure of infestation, defined as no evidence of head lice, assessed between completion of the second application of treatment on day 7 and day 14 (the first treatment being applied on day 0).
Secondary outcome measures1. Comparison of the efficacy of Liceko® with that of Nix® / Lyclear® crème rinse and to identify superiority of one product over the other if appropriate.
2. Safety of the products monitored by observation for adverse events on days 0, 1, 6, 7, 9, and 14 of the study
Overall study start date01/07/2011
Completion date31/10/2011

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit6 Months
SexBoth
Target number of participants44 divided into two groups of 22
Key inclusion criteria1. Both males and females, aged 6 months and over with no upper age limit
2. People who upon examination, are confirmed to have live head lice
3. People who give written informed consent, or if the participant is under 16 years of age whose parent/guardian gives written informed consent to participate in the study
4. People who will be available for follow-up visits by study team members over the 14 days following first treatment
Key exclusion criteria1. People with a known sensitivity to any of the ingredients in Liceko ® or Nix® / Lyclear® 1% permethrin creme rinse, pyrethroid insecticides, or plants related to dandelions or chrysanthemums.
2. People with a secondary bacterial infection of the scalp (e.g. impetigo) or who have an active long-term scalp condition (e.g. psoriasis of the scalp)
3. People who have been treated with other head lice products within the previous two weeks
4. People who have bleached hair, or hair that has been permanently waved within the previous four weeks
5. People who have been treated with the antibiotics co-trimoxazole or trimethoprim within the previous four weeks, or who are currently taking such a course
6. Pregnant or nursing mothers
7. People who have participated in another clinical study within one month before entry to this study
8. People who have already participated in this clinical study
Date of first enrolment01/07/2011
Date of final enrolment31/10/2011

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Medical Entomology Centre
Cambridge
CB25 9AU
United Kingdom

Sponsor information

Panin S.R.L (Italy)
Industry

Viale Della Scienza 24
Rovigo
45100
Italy

Phone +39 (0)42 547 1323
Email f.astolfi@panin.it
Website http://www.panin.it/
ROR logo "ROR" https://ror.org/00c5hbd86

Funders

Funder type

Industry

Panin S.R.L (Italy)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 03/09/2013 Yes No